Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Plasmacytoma 2Paraproteinemias 2Multiple Myeloma 2Leukemia, Plasma Cell 2Patient Preference 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leiomyoma 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1Agnosia 1Advanced Solid Tumors 1Advanced Cancer 1Abdominal Cancer 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Injections, Subcutaneous × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡